Stock Track | AgomAb Therapeutics Plummets 8.13% in Intraday Trading on Disappointing Nasdaq Debut

Stock Track

Feb 07

AgomAb Therapeutics' stock plummeted 8.13% intraday as the biopharmaceutical company made its disappointing debut on the Nasdaq exchange.

The Belgium-based company, which focuses on developing treatments for immune and inflammatory diseases, saw its American Depositary Shares open significantly below its initial public offering price of $16 per share. The stock's weak opening reflects investor concerns despite the company successfully raising $200 million through its IPO.

AgomAb's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven strictures that often require surgical intervention. The company's market debut below its offering price suggests tempered investor enthusiasm for its clinical pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1163176710"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163176710\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163176710?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-07 01:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163176710","market":"hk","top_or_hot":-1,"title":"Stock Track | AgomAb Therapeutics Plummets 8.13% in Intraday Trading on Disappointing Nasdaq Debut","media":"Stock Track","content":"<p>AgomAb Therapeutics' stock plummeted 8.13% intraday as the biopharmaceutical company made its disappointing debut on the Nasdaq exchange.</p><p>The Belgium-based company, which focuses on developing treatments for immune and inflammatory diseases, saw its American Depositary Shares open significantly below its initial public offering price of $16 per share. The stock's weak opening reflects investor concerns despite the company successfully raising $200 million through its IPO.</p><p>AgomAb's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven strictures that often require surgical intervention. The company's market debut below its offering price suggests tempered investor enthusiasm for its clinical pipeline.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | AgomAb Therapeutics Plummets 8.13% in Intraday Trading on Disappointing Nasdaq Debut</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | AgomAb Therapeutics Plummets 8.13% in Intraday Trading on Disappointing Nasdaq Debut\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-07 01:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AgomAb Therapeutics' stock plummeted 8.13% intraday as the biopharmaceutical company made its disappointing debut on the Nasdaq exchange.</p><p>The Belgium-based company, which focuses on developing treatments for immune and inflammatory diseases, saw its American Depositary Shares open significantly below its initial public offering price of $16 per share. The stock's weak opening reflects investor concerns despite the company successfully raising $200 million through its IPO.</p><p>AgomAb's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven strictures that often require surgical intervention. The company's market debut below its offering price suggests tempered investor enthusiasm for its clinical pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGMB","symbol_name":"AgomAb Therapeutics","start_time":0,"source_url":"","article_id":"1163176710","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163176710","pubTimestamp":1770399909,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"AgomAb Therapeutics' stock plummeted 8.13% intraday as the biopharmaceutical company made its disappointing debut on the Nasdaq exchange.The Belgium-based company, which focuses on developing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGMB":"AgomAb Therapeutics"},"translate_title":"个股追踪|AgomAb Therapeutics纳斯达克首秀令人失望盘中暴跌8.13%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGMB":1},"content_text":"AgomAb Therapeutics' stock plummeted 8.13% intraday as the biopharmaceutical company made its disappointing debut on the Nasdaq exchange.The Belgium-based company, which focuses on developing treatments for immune and inflammatory diseases, saw its American Depositary Shares open significantly below its initial public offering price of $16 per share. The stock's weak opening reflects investor concerns despite the company successfully raising $200 million through its IPO.AgomAb's lead product candidate, ontunisertib, is being developed for fibrostenosing Crohn's disease, a severe form of Crohn's characterized by inflammation-driven strictures that often require surgical intervention. The company's market debut below its offering price suggests tempered investor enthusiasm for its clinical pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}